18889881171
Kalkine 0
countryflagUS

SINOPHARM GROUP CO LTD ADR

Healthcare US SHTDY

11.91USD
0.04(0.34%)

Last update at 2025-07-11T15:11:00Z

Day Range

11.9111.92
LowHigh

52 Week Range

11.7517.37
LowHigh

Fundamentals

  • Previous Close 11.87
  • Market Cap7601.92M
  • Volume139
  • P/E Ratio6.18
  • Dividend Yield4.70%
  • EBITDA24589.56M
  • Revenue TTM591685.68M
  • Revenue Per Share TTM949.16
  • Gross Profit TTM 47434.06M
  • Diluted EPS TTM1.97

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 18563.82M 17003.16M 15598.10M 13759.81M 12207.94M
Minority interest -5819.78700M -5306.12700M 33588.48M 29517.22M 25453.94M
Net income 8525.66M 7758.65M 7187.28M 6252.54M 5835.84M
Selling general administrative 8183.56M 7760.99M 7049.81M 6912.23M 5517.88M
Selling and marketing expenses 16719.56M 15437.53M 14141.74M 12556.93M 10369.83M
Gross profit 47434.06M 44050.61M 40323.31M 37531.30M 31228.09M
Reconciled depreciation 4165.02M 3922.06M 3597.11M 3114.08M 1394.68M
Ebit 24644.21M 22942.99M 21308.49M 19685.45M 16672.70M
Ebitda 28809.23M 26865.05M 24905.60M 22799.53M 18067.38M
Depreciation and amortization 4165.02M 3922.06M 3597.11M 3114.08M 1394.68M
Non operating income net other - - - - 0.00000M
Operating income 20604.47M 19711.98M 17759.97M 16136.74M 15396.81M
Other operating expenses 528940.45M 499609.96M 436630.85M 406769.41M 328771.68M
Interest expense 3520.33M 3756.84M 3424.76M 3442.51M 4157.25M
Tax provision 4218.38M 3938.39M 3500.80M 3139.74M 2803.46M
Interest income 542.77M 558.56M 676.36M 519.44M 513.42M
Net interest income -3189.99200M -3402.86900M -2944.18900M -3137.42400M -4095.22800M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 4218.38M 3938.39M 3500.80M 3139.74M 2803.46M
Total revenue 552147.55M 521051.23M 456414.61M 425272.73M 344525.82M
Total operating expenses 24226.96M 22609.33M 20539.55M 19027.99M 15473.95M
Cost of revenue 504713.49M 477000.63M 416091.30M 387741.42M 313297.73M
Total other income expense net -2040.64700M -2708.81400M -2161.87900M -2376.93400M -3188.86600M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 14345.44M 13064.77M 12097.29M 10620.07M 9404.48M
Net income applicable to common shares 8525.66M 7758.65M 7187.20M 6251.35M 5833.55M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 364775.13M 335412.32M 311236.71M 269888.37M 235771.08M
Intangible assets 4870.15M 5002.96M 5271.83M 5133.39M 2598.35M
Earning assets - - - - -
Other current assets 24326.81M 16796.41M 18225.97M 19419.47M 16878.10M
Total liab 254705.94M 235758.39M 221289.39M 192949.00M 167495.31M
Total stockholder equity 68068.56M 61886.01M 56358.85M 47422.15M 42821.83M
Deferred long term liab 74.44M 76.61M 81.26M 66.34M 50.05M
Other current liab 35713.07M 29739.98M 30880.44M 25835.24M 22273.45M
Common stock 3120.66M 3120.66M 3120.66M 2971.66M 2971.66M
Capital stock 3120.66M 3120.66M 3120.66M 2971.66M 2971.66M
Retained earnings 44700.83M 38515.78M 32908.14M 27588.04M 23089.67M
Other liab 4785.99M 4783.29M 5150.55M 3054.03M 2401.83M
Good will 7155.58M 7199.01M 7287.39M 5664.07M 4899.38M
Other assets 5784.65M 5583.03M 5609.97M 5082.59M 5599.57M
Cash 55221.62M 43529.43M 50178.26M 39191.97M 40298.99M
Cash and equivalents - - - - -
Total current liabilities 234962.96M 219306.55M 203977.10M 178424.63M 160074.38M
Current deferred revenue 28000.70M 21620.40M 22867.98M 17416.26M 15950.23M
Net debt 14368.56M 24838.82M 18348.56M 15947.29M 14805.33M
Short term debt 54633.19M 56699.70M 56365.09M 43668.92M 50085.22M
Short long term debt 52997.25M 55151.65M 54958.95M 42476.71M 50085.22M
Short long term debt total 69590.19M 68368.25M 68526.83M 55139.25M 55104.32M
Other stockholder equity 64947.90M 58765.36M 53238.19M 44450.49M 39850.17M
Property plant equipment 19647.16M 19407.75M 18895.85M 18063.04M 11025.14M
Total current assets 319406.38M 290922.14M 267609.97M 229999.69M 204654.57M
Long term investments - - - - 7065.11M
Net tangible assets 57972.08M 51570.90M 45710.80M 38499.64M 35395.14M
Short term investments 0.50M 11.75M 39.14M 0.16M 41.20M
Net receivables 155578.57M 176273.39M 149448.35M 126591.70M 110363.73M
Long term debt 11750.43M 8418.68M 8918.73M 8372.85M 4951.17M
Inventory 60925.83M 51499.62M 47085.45M 42594.40M 35388.86M
Accounts payable 144616.69M 132866.87M 116731.57M 108920.48M 87715.71M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 3730.96M 3731.08M 3954.79M 3511.00M 2830.25M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 45368.75M 44490.18M 43626.73M 39888.68M 31116.50M
Capital lease obligations 4842.51M 4797.92M 4649.15M 4289.69M 67.93M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -3589.62200M -8.15200M 23.16M -113.98100M -498.30100M
Change to liabilities 12629.54M 18539.94M 13816.56M 16734.30M 14735.85M
Total cashflows from investing activities -3589.62200M -1266.96200M -2202.75800M -6795.96700M -5907.62400M
Net borrowings 2920.78M -6542.55900M 6436.55M -5468.43400M 14282.91M
Total cash from financing activities -5693.48100M -14693.00700M 2025.85M -13084.56500M 10318.52M
Change to operating activities -5909.13700M 421.26M 3770.27M 2815.32M 3916.93M
Net income 18563.82M 17003.16M 15598.10M 13759.81M 12207.94M
Change in cash 11692.20M -6648.83700M 10986.30M -1107.01800M 8058.19M
Begin period cash flow 43529.43M 50178.26M 39191.97M 40298.99M 32240.80M
End period cash flow 55221.62M 43529.43M 50178.26M 39191.97M 40298.99M
Total cash from operating activities 20963.79M 9308.08M 11154.61M 18777.10M 3653.74M
Issuance of capital stock - 0.00000M 3600.40M 50.15M 2.83M
Depreciation 4165.02M 3922.06M 3597.11M 3114.08M 1394.68M
Other cashflows from investing activities -1027.56300M 1324.12M 2115.67M -3296.08200M -2045.59200M
Dividends paid -2340.49200M -2153.25300M -1865.12300M -1753.27700M 1577.03M
Change to inventory -9504.22400M -4345.33200M -3675.40400M -6120.22300M -4925.87200M
Change to account receivables 710.12M -26717.20100M -22631.38400M -12965.40600M -24392.23800M
Sale purchase of stock - - 96841.35M 78854.48M 75950.51M
Other cashflows from financing activities 98352.35M 92167.35M 97128.75M 79917.30M 78655.31M
Change to netincome 10362.68M 9741.34M 9013.95M 8946.49M 7088.55M
Capital expenditures 2417.53M 2255.64M 2087.32M 2548.83M 3404.12M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -2073.70100M -12101.33300M -8719.96300M 463.99M -10665.33000M
Stock based compensation - 0.00000M -18.56900M 5.75M 19.98M
Other non cash items 308.65M 484.20M 697.93M 1433.47M 696.47M
Free cash flow 18546.26M 7052.44M 9067.28M 16228.26M 249.62M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SHTDY
SINOPHARM GROUP CO LTD ADR		 0.04 0.34% 11.91 6.18 7.49 0.01 0.76 0.03 0.72
MCK
McKesson Corporation		 0.84 0.12% 710.43 17.95 14.53 0.20 5.04 0.22 12.17
COR
Cencora Inc.		 1.04 0.35% 296.25 23.39 - - -
CAH
Cardinal Health Inc		 0.56 0.34% 161.53 166.11 14.71 0.12 16.07 0.12 19.78
HSIC
Henry Schein Inc		 -2.785 3.79% 70.64 24.12 14.04 0.74 2.50 0.95 13.33

Reports Covered

Stock Research & News

View All

Profile

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

SINOPHARM GROUP CO LTD ADR

Sinopharm Group Building, Shanghai, China, 200023

Key Executives

Name Title Year Born
Mr. Qingming Yu Exec. Chairman 1964
Mr. Yong Liu Pres & Exec. Director 1969
Mr. Xiuchang Jiang CFO & VP 1964
Ms. Xiaojuan Li Chief Financial Officer 1976
Mr. Yijian Wu Sec. to the Board, Company Sec. & Authorised Representative 1970
Mr. Wanyong Lian VP 1971
Mr. Shuangjun Xu Non-Exec. VP 1969
Mr. Maisong Cai VP 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.